Back to News
Market Impact: 0.4
Geron Corporation Discontinues Phase 3 IMpactMF Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Geron Corporation announced on October 28, 2026, that it would discontinue the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. The decision followed a recommendation from the independent Data Monitoring Committee; the provided article text ends before stating the committee’s rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.55
Ticker Sentiment
GERN-0.85
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- PC chip plunge wipes out a quarter of Intel’s value
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up